Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Identifying Areas of Unmet Need Among People with Migraine with an Inadequate Response to Prior Acute Therapies: Results from the MOMENTUM trial
Headache
P7 - Poster Session 7 (8:00 AM-9:00 AM)
2-009

A better understanding of the key areas of unmet need regarding acute migraine therapy may help inform drug development and treatment selection.

The objective of this study was to characterize the areas of greatest unmet needs regarding acute migraine therapy, as determined by the 4-item Migraine Treatment Optimization Questionnaire (mTOQ-4).

The Phase 3 MOMENTUM trial (N=1594) assessed the efficacy and safety of AXS-07 (MoSEIC™ meloxicam and rizatriptan), meloxicam alone, rizatriptan alone, and placebo in a 4-arm acute migraine treatment trial.  Eligible patients had to have a history of inadequate response to prior acute treatments, assessed using the mTOQ-4, prior to enrollment. 

The mTOQ-4 assesses the frequency of efficacy response to acute treatment in four domains: Q1: two-hour pain freedom (2hPF), Q2: sustained pain freedom (SPF), Q3: ability to plan daily activities, and Q4: disruption of daily activities.  Response options included: never (0), rarely (0), less than half the time (1), or half the time or more (2).

For this analysis, we examined the proportion of subjects responding "Never" or "Rarely" to each of the mTOQ items to characterize the relative frequency of unmet need in each mTOQ domain.

At baseline, the mean total mTOQ score was 3.6, indicating poor response to prior acute therapies.  The proportions of participants answering "Never" or "Rarely" to the individual mTOQ items were: 33.4% for 2hPF, 43.2% for SPF, 40.5% for ability to plan, and 29.3% for disruption of daily activity.

Between 29-43% of people with migraine rarely or never experience a positive efficacy response to each of the four mTOQ domains.  Novel therapies that provide sustained pain freedom and improve the perceived ability to plan daily activities are particularly needed. 

Authors/Disclosures
Zachariah Thomas
PRESENTER
Zachariah Thomas has received personal compensation for serving as an employee of Axsome. Zachariah Thomas has stock in Axsome .
No disclosure on file
Angad Chhabra No disclosure on file
Shawn Alter, PhD (Axsome) Dr. Alter has received personal compensation for serving as an employee of Axsome Therapeutics. Dr. Alter has stock in Axsome Therapeutics.
Herriot Tabuteau (Axsome Therapeutics) No disclosure on file
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in Manistee. Dr. Lipton has stock in Axon. Dr. Lipton has stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.